{
  "Study_ID": "deSouza2010",
  "First_Author": "de Souza A",
  "Year": "2010",
  "Country": "India",
  "Study_Design": "Randomized controlled trial with serial MRI follow-up",
  "Risk_of_Bias": "Moderate - randomization by random number table but unblinded clinicians",
  "Diagnostic_Criteria": "MRI-confirmed solitary cysticercal lesion in cerebral parenchyma, new-onset focal or generalized seizures",
  "Total_Sample_Size": "123 (81 completed follow-up)",
  "Treatment_Group_N": "37",
  "Control_Group_N": "44",
  "Age_Mean_SD": "Treatment: 20.54 Â± 9.34, Control: 18.09 Â± 11.75 years",
  "Male_Percentage": "50.6 (41/81)",
  "Female_Percentage": "49.4 (40/81)",
  "Other_Demographics": "56.8% less than 18 years old",
  "Headache_Percentage": "Not specifically reported",
  "Focal_Seizures_Percentage": "Not specified",
  "Other_Symptoms": "Not reported",
  "Treatment_Type": "Albendazole plus antiepileptics vs antiepileptics alone",
  "Albendazole_Dose": "15 mg/kg/day in two divided doses",
  "Treatment_Duration_Days": "28",
  "Number_of_Cycles": "1",
  "Cycle_Interval_Days": "Not applicable",
  "Praziquantel_Dose": "Not used",
  "Corticosteroid_Type": "Not used",
  "Antiepileptic_Drug": "Phenytoin, Carbamazepine or Oxcarbazepine",
  "Follow_up_Duration_Months": "24",
  "Imaging_Schedule": "Baseline, 3, 6, 12 and 24 months",
  "Complete_Resolution_Percentage": "43.9% at 24 months (both groups combined)",
  "Partial_Resolution_Percentage": "Not directly specified",
  "No_Change_Percentage": "18.8% in stage 3 persisted unchanged for mean 17.4 months",
  "Seizure_Reduction_Percentage": "Not specifically reported",
  "Elevated_Liver_Enzymes_Percentage": "Not reported",
  "Other_AE": "Not reported",
  "Comments": "No significant difference between albendazole and control groups in lesion evolution or resolution. Treatment only showed faster decline in perilesional edema at 3 months. Natural history follows predictable sequence over >1 year regardless of treatment.",
  "last_modified": "2024-10-31T14:51:17.399931"
}